Chassignolle 1994.

Study characteristics
Methods	Study design: randomised, double‐blind, placebo‐controlled Method of randomisation: not stated Exclusions post randomisation: none Losses to follow‐up: 4/40 (10%)
Participants	Country: France Setting: hospital Number: 40 patients Age: 32.0 (1.3) years active group; 35.6 (1.1) years placebo group Gender: female Inclusion criteria: women with functional CVI Exclusion criteria: not stated
Interventions	Treatment: diosmine 1000 mg per day Control: placebo Duration: 60 days Follow‐up: 60 days
Outcomes	Primary Plethysmographic parameters CVI symptoms ‐ heaviness, pain, tiredness, itching, paraesthesias and cramps measured by an ordinal scale (0 to 4). Global evaluation of symptoms (score functional) CVI signs ‐ oedema, cyanosis, redness, leg heat and induration measured by an ordinal scale (0 to 4). Global evaluation of signs (score objective) Tolerance Secondary Not stated
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Patients were randomly assigned to two parallel groups of 20" Comment: no randomisation methods stated
Allocation concealment (selection bias)	Unclear risk	Comment: no methods of allocation concealment stated
Blinding (patients)	Unclear risk	Comment: no information given about methods used for blinding
Blinding (study researchers)	Unclear risk	Comment: no information given about methods used for blinding
Blinding (outcome assessment)	Unclear risk	Comment: no information given about methods used for blinding
Incomplete outcome data	Low risk	Comment: number of participants in each group described, number of participants who dropped out prematurely stated and reasons for dropping out described
Selective reporting	Low risk	Comment: no published protocol identified, and no differences between outcomes reported in the methods section and those reported in the results section
Other bias	Low risk	Comment: none detected